About: Multi-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection Kit

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multi-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection Kit Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Multi-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection Kit
Creator	Li, Tao Vinetz, Joseph Wang, Linda Ko, Albert Spiegel, David Casanovas-Massana, Arnau Levine, Morgan Howell, Rebecca Caianiello, David Collinski, Jesse Deramon, Edward Hale, Robert Mcdonald, David Minteer, Christopher Pan, Si Ray, Jason
topic	covid:8c53cb10b0f7a91a75d8b2dfa7545edd8be77ff8#this
source	MedRxiv
abstract	Deaths from coronavirus disease (COVID-19) have exceeded 300,000 persons globally, calling for rapid development of mobile diagnostics that can assay widespread prevalence and infection rates. Data provided in this study supports the utility of a newly-designed lateral flow immunoassay (LFA) for detecting SARS-CoV-2 IgM and IgG antibodies. We employed a clinical cohort of 1,892 SARS-CoV-2 patients and controls, including individuals diagnosed by RT-qPCR at Yale New Haven Hospital, The First Affiliated Hospital of Anhui Medical University, the Chinese Center for Disease Control and Prevention of Hefei City (Hefei CDC), Anhui Province (Anhui Province CDC), and Fuyang City (Fuyang CDC). The LFA studied here detects SARS-CoV-2 IgM and IgG antibodies with a specificity of 97.9-100% for IgM, 99.7-100% for IgG, and sensitivities ranging from 94.1-100% for patients >14-days post symptom onset. Sensitivity decreases in patients <14-days post symptom onset, which is likely due to lower IgG/IgM antibody levels in this population. Finally, we developed a visual intensity reporting system that we believe will be suitable for laboratory and point-of-care settings, and will provide granular information about antibody levels. Overall our results support the widespread utility of this and other LFAs in assessing population-level epidemiological statistics.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.25.20112227
has license	medrxiv
sha1sum (hex)	8c53cb10b0f7a91a75d8b2dfa7545edd8be77ff8
schema:url	https://doi.org/10.1101/2020.05.25.20112227
resource representing a document's title	Multi-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection Kit
resource representing a document's body	covid:8c53cb10b0f7a91a75d8b2dfa7545edd8be77ff8#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/8c53cb10b0f7a91a75d8b2dfa7545edd8be77ff8
is schema:about of	named entity 'infection' named entity 'patients' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'UNIVERSITY' named entity 'AFFILIATED' named entity 'CLINICAL' named entity 'FUYANG CITY' named entity 'NEW HAVEN' named entity 'SPECIFICITY' named entity 'RAPID' named entity 'LIKELY' named entity 'EXCEEDED' named entity 'UTILITY' named entity 'INTENSITY' named entity 'POST' named entity 'CDC' named entity 'SETTINGS' named entity 'MEDICAL' named entity 'immunoassay' named entity 'Center' named entity 'population' named entity 'ranging' named entity 'developed' named entity 'RT-qPCR' named entity 'Overall' named entity 'symptom' named entity 'detecting' named entity 'onset' named entity 'Detection' named entity 'SARS-CoV-2' named entity 'symptom' named entity 'IgG antibodies' named entity 'IgG' named entity 'Affiliated Hospital' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'IgG antibodies' named entity 'Anhui Province' named entity 'point-of-care' named entity 'antibody' named entity 'levels' named entity 'SARS-CoV-2' named entity 'Fisher test' named entity 'infection' named entity 'virus' named entity 'IgG' named entity 'clinical samples' named entity 'antibody' named entity 'lateral flow' named entity 'infection' named entity 'United States government' named entity 'negative result' named entity 'IgM' named entity 'antigen' named entity 'IgM' named entity 'general population' named entity 'IgG' named entity 'health-care professionals' named entity 'sensitivity and specificity' named entity 'infection' named entity 'SARS-CoV-2' named entity 'Yale New Haven Hospital' named entity 'antigens' named entity 'Hefei' named entity 'respiratory infections' named entity 'IgM' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software